ABEO — Abeona Therapeutics Share News
0.000.00%
Last trade - 00:00- $260.76m
- $128.92m
- $5.82m
Abeona Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Smithfield Foods, Altria, Sherwin-Willams
U.S. STOCKS ON THE MOVE-JetBlue, Hims & Hers, Okta
U.S. STOCKS ON THE MOVE-General Motors, Pfizer, PayPal
U.S. STOCKS ON THE MOVE-Spotify, Abeona, Honeywell
Abeona rises on FDA approval for skin disorder therapy
Brief: US FDA Approves ZEVASKYN, First And Only Cell-Based Gene Therapy For Patients With Recessive Dystrophic Epidermolysis Bullosa
US FDA approves Abeona's skin disorder therapy (updated)
US FDA approves Abeona's skin disorder therapy
Abeona Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Abeona Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview
Brief: Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Abeona Therapeutics Announces FDA Acceptance Of BLA Resubmission Of Pz-cel For The Treatment Of Recessive Dystrophic Epidermolysis Bullosa
Abeona Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)